Want to see ALDX full AI Analyst Report?
ALDX Stock Chart & Stats
$1.80
-$0.07(-1.37%)
At close: 4:00 PM EST
$1.80
-$0.07(-1.37%)
Day’s Range― - ―
52-Week Range$1.07 - $6.18
Previous CloseN/A
Volume102.94K
Average Volume (3M)1.04M
Market Cap
$110.39M
Enterprise Value$60.90M
Total Cash (Recent Filing)$65.00M
Total Debt (Recent Filing)$15.51M
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Jul 31, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding60,321,068
10 Day Avg. Volume1,169,475
30 Day Avg. Volume1,038,564
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-472.51
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$2.00Price Target Upside11.11% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$21.72M
Bulls Say, Bears Say
Bulls Say
Strengthened GovernanceAdding an independent, financially expert director and audit chair enhances board oversight and financial governance. Stronger audit and governance oversight improves credibility with regulators and investors, reduces execution risk on filings and financing, and supports more disciplined capital allocation over time.
Improved Liquidity RunwayPaying off the Hercules loan reduces interest obligations and counterparty covenants, increasing financial flexibility. A disclosed cash runway into 2028 lowers near-term fundraising pressure, permitting more deliberate development and regulatory work without immediate dilution risk, strengthening execution prospects.
Platform & Pipeline OptionalityA multi-indication RASP-modulation platform provides diversification beyond a single asset and creates multiple clinical and commercial pathways. Clearer endpoint analyses and standardized estimates improve program planning and increase the odds that some indications deliver durable value if clinical/regulatory hurdles are overcome.
Bears Say
Regulatory SetbackA second Complete Response Letter materially raises the probability of additional studies, prolonged review timelines, or substantial label restrictions. This increases development cost and timing risk, undermining near- and mid-term commercialization prospects and heightening dependence on capital markets to fund further work.
No Revenue / Persistent LossesLack of product revenue and repeated operating losses mean value creation depends entirely on future clinical and regulatory success. Continued negative profitability erodes equity value and forces reliance on external financing, which can dilute shareholders and constrain long-term strategic options if trials falter.
Volatile Cash Flow QualityConsistently negative operating and free cash flow indicate structural cash burn to fund R&D. The atypical TTM swing reduces confidence in predictable cash generation; without steady positive cash flow, the company remains exposed to fundraising cycles and execution risk that can impair long-term program continuity.
Aldeyra Therapeutics News
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.07 and its highest was $6.17 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $110.39M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is Jul 31, 2026 which is in 31 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on May 07, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.098 by $0.038.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,321,068 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.098. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (11.11% Upside)
$2.00 (11.11% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $417.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.71%
12-Months-Change
Fundamentals
Return on Equity
-57.34%
Trailing 12-Months
Asset Growth
-28.66%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Stock 12 Month Forecast
Average Price Target
$2.00
▲(11.11% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.66% Insiders
8.73% Mutual Funds
21.91% Other Institutional Investors
58.07% Public Companies and
Individual Investors